Physician profile
James Prezzano
NPI 1538554753
$11,889.48
in general payments reported to CMS, 2019-2025
26 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.95 · 2020: $181 · 2021: $1,034 · 2022: $2,397 · 2023: $2,614 · 2024: $2,612 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,092 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,092.04 |
| Education | $114.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.24 | 2021-2025 | |
| Incyte Corporation | $1,308.36 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $1,263.99 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $833.98 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $794.57 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $746.39 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $672.64 | 2022-2025 | |
| Dermavant Sciences, INC. | $672.49 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $571.89 | 2021-2025 | |
| Amgen INC. | $523.18 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $451.62 | 2022-2025 | Sotyktu |
| Pfizer INC. | $406.22 | 2021-2025 | |
| Leo Pharma INC. | $391.75 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $369.16 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $307.97 | 2021-2025 | Siliq, Duobrii, Cabtreo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $210.27 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $138.53 | 2021-2025 | Nemluvio |
| Organon LLC | $113.37 | 2025 | Vtama |
| Genentech USA, INC. | $84.65 | 2020 | |
| Vyne Pharmaceuticals INC. | $79.70 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $62.30 | 2021-2025 | Valchlor |
| Biofrontera INC. | $43.77 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.92 | 2022-2023 | Spevigo |
| Fresenius Kabi USA, LLC | $41.64 | 2023 | Idacio |
| Mimedx Group, INC. | $37.79 | 2025 | |
| Merck Sharp & Dohme LLC | $13.09 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Prezzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.